Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma Ltd. has announced IRB approval to begin a Phase IIa study of Namodenoson for treating pancreatic cancer at Israel’s Rabin Medical Center. The study will assess the drug’s safety and efficacy in patients with advanced pancreatic adenocarcinoma. Namodenoson has previously shown promise in pre-clinical models and has received peer-reviewed recognition for its potential in combating pancreatic cancer.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
